Molecular subtypes of pancreatic cancer
Cancers that appear morphologically similar often have dramatically different clinical
features, respond variably to therapy and have a range of outcomes. Compelling evidence …
features, respond variably to therapy and have a range of outcomes. Compelling evidence …
Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter
G Luo, K Jin, S Deng, H Cheng, Z Fan, Y Gong… - … et Biophysica Acta (BBA …, 2021 - Elsevier
Abstract Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an
indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker …
indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker …
[HTML][HTML] Carbohydrate antigen 19-9—Tumor marker: Past, present, and future
T Lee, TZJ Teng, VG Shelat - World journal of gastrointestinal …, 2020 - ncbi.nlm.nih.gov
Abstract Carbohydrate antigen 19-9 (CA 19-9) is a cell surface glycoprotein complex most
commonly associated with pancreatic ductal adenocarcinoma (PDAC). Koprowski first …
commonly associated with pancreatic ductal adenocarcinoma (PDAC). Koprowski first …
Bimetallic cerium and ferric oxides nanoparticles embedded within mesoporous carbon matrix: electrochemical immunosensor for sensitive detection of carbohydrate …
M Wang, M Hu, B Hu, C Guo, Y Song, Q Jia… - Biosensors and …, 2019 - Elsevier
A label-free electrochemical immunosensor was successfully developed for sensitively
detecting carbohydrate antigen 19–9 (CA19-9) as a cancer marker. To achieve this, a series …
detecting carbohydrate antigen 19–9 (CA19-9) as a cancer marker. To achieve this, a series …
The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates
KE Poruk, DZ Gay, K Brown… - Current molecular …, 2013 - ingentaconnect.com
CA 19-9 and CEA are the most commonly used biomarkers for diagnosis and management
of patients with pancreatic cancer. Since the original compendium by Steinberg in 1990 …
of patients with pancreatic cancer. Since the original compendium by Steinberg in 1990 …
Importance of normalization of CA19-9 levels following neoadjuvant therapy in patients with localized pancreatic cancer
Objective: Carbohydrate antigen 19-9 (CA19-9) is a prognostic marker for patients with
pancreatic cancer (PC), but its value as a treatment biomarker is unclear. Summary …
pancreatic cancer (PC), but its value as a treatment biomarker is unclear. Summary …
CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy
W Hartwig, O Strobel, U Hinz, S Fritz, T Hackert… - Annals of surgical …, 2013 - Springer
Purpose In pancreatic cancer, genetic markers to aid clinical decision making are still
lacking. The present study was designed to determine the prognostic role of perioperative …
lacking. The present study was designed to determine the prognostic role of perioperative …
Advanced-stage pancreatic cancer: therapy options
J Werner, SE Combs, C Springfeld, W Hartwig… - Nature reviews Clinical …, 2013 - nature.com
Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, and surgical
resection is a requirement for a potential cure. However, the majority of patients are …
resection is a requirement for a potential cure. However, the majority of patients are …
Investigating the regulatory role of miRNAs as silent conductors in the management of pathogenesis and therapeutic resistance of pancreatic cancer
Pancreatic cancer (PC) has the greatest mortality rate of all the main malignancies. Its
advanced stage and poor prognosis place it at the bottom of all cancer sites. Hence …
advanced stage and poor prognosis place it at the bottom of all cancer sites. Hence …
An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: a multicenter cohort study
Abstract Background & Aims Pancreatic ductal adenocarcinoma (PDAC) incidence is rising
worldwide, and most patients present with an unresectable disease at initial diagnosis …
worldwide, and most patients present with an unresectable disease at initial diagnosis …